Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second registration study of TTP399 for Type 1 Diabetes (T1D)

Next Previous
X
Search
Trial Profile

A second registration study of TTP399 for Type 1 Diabetes (T1D)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cadisegliatin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 01 Nov 2023 According to a vTv Therapeutics LLC media release, the company has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. through which Reneo has purchased all of its common stock that was granted to vTv under the Reneo License Agreement for total proceeds to vTv of approximately $4.4 million, The proceeds from the sale of our Reneo stock will provide vTv with important financial support as we continue preparations for the launch of the cadisegliatin Phase 3 program
    • 06 Mar 2023 According to a vTv Therapeutics LLC media release, both studies are expected to recruit approximately 1,000 patients and at least one of the studies will assess one year of treatment.
    • 29 Mar 2022 According to a vTv Therapeutics media release, this study expected to start in 3Q 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top